These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26987376)

  • 1. Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial.
    Lee FJ; Monteiro P; Baker D; Bloch M; Roth N; Finlayson R; Moore R; Hoy J; Martinez E; Carr A
    HIV Med; 2016 Sep; 17(8):605-14. PubMed ID: 26987376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
    Calza L; Magistrelli E; Colangeli V; Borderi M; Bussini L; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2017 Oct; 49(10):737-747. PubMed ID: 28683645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors.
    Calza L; Manfredi R; Colangeli V; Pocaterra D; Pavoni M; Chiodo F
    Curr HIV Res; 2008 Nov; 6(6):572-8. PubMed ID: 18991624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
    van der Lee M; Sankatsing R; Schippers E; Vogel M; Fätkenheuer G; van der Ven A; Kroon F; Rockstroh J; Wyen C; Bäumer A; de Groot E; Koopmans P; Stroes E; Reiss P; Burger D
    Antivir Ther; 2007; 12(7):1127-32. PubMed ID: 18018771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
    Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
    HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
    Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides.
    Di Biagio A; Riccardi N; Taramasso L; Capetti A; Cenderello G; Signori A; Vitiello P; Guerra M; de Socio GV; Cassola G; Quirino T; Viscoli C
    Int J Antimicrob Agents; 2016 Nov; 48(5):551-554. PubMed ID: 27566908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
    AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor.
    Bittar R; Giral P; Aslangul E; Assoumou L; Valantin MA; Kalmykova O; Federspiel MC; Cherfils C; Costagliola D; Bonnefont-Rousselot D;
    AIDS; 2012 Sep; 26(14):1801-5. PubMed ID: 22739396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
    Tomaka F; Lefebvre E; Sekar V; Van Baelen B; Vangeneugden T; Vandevoorde A; Diego Miralles G
    HIV Med; 2009 May; 10(5):318-27. PubMed ID: 19210693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.
    Martinez E; Gonzalez-Cordon A; Ferrer E; Domingo P; Negredo E; Gutierrez F; Portilla J; Curran A; Podzamczer D; Murillas J; Bernardino JI; Santos I; Carton JA; Peraire J; Pich J; Perez I; Gatell JM;
    HIV Med; 2014 Jul; 15(6):330-8. PubMed ID: 24417772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients.
    Saeedi R; Johns K; Frohlich J; Bennett MT; Bondy G
    Lipids Health Dis; 2015 Jun; 14():57. PubMed ID: 26087958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial.
    Aberg JA; Sponseller CA; Ward DJ; Kryzhanovski VA; Campbell SE; Thompson MA
    Lancet HIV; 2017 Jul; 4(7):e284-e294. PubMed ID: 28416195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study.
    Masiá M; Martínez E; Padilla S; Gatell JM; Gutiérrez F
    J Antimicrob Chemother; 2013 Feb; 68(2):409-13. PubMed ID: 23075691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.
    Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Alberto Arnaiz J; Cooper D; Rockstroh JK; Mallon P; Emery S;
    HIV Med; 2018 Jan; 19(1):65-71. PubMed ID: 28703491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.
    Gatell JM; Assoumou L; Moyle G; Waters L; Johnson M; Domingo P; Fox J; Martinez E; Stellbrink HJ; Guaraldi G; Masia M; Gompels M; De Wit S; Florence E; Esser S; Raffi F; Stephan C; Rockstroh J; Giacomelli A; Vera J; Bernardino JI; Winston A; Saumoy M; Gras J; Katlama C; Pozniak AL;
    Clin Infect Dis; 2019 Feb; 68(4):597-606. PubMed ID: 29912307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.
    Gatell JM; Assoumou L; Moyle G; Waters L; Johnson M; Domingo P; Fox J; Martinez E; Stellbrink HJ; Guaraldi G; Masia M; Gompels M; De Wit S; Florence E; Esser S; Raffi F; Pozniak AL;
    AIDS; 2017 Nov; 31(18):2503-2514. PubMed ID: 29112070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.